Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Advanced Refractory Biliary Tract Cancers
NCT02829918Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2016
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in biliary tract cancer (BTC), sponsored by Moffitt Cancer Center. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02829918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829918.